Ernst & Young unveils 'Health Quotient' for Indian pharma market

March 2006
Chemical Business;Mar2006, Vol. 20 Issue 3, p70
Trade Publication
Focuses on the release of a report on the issues and opportunities in the pharmaceuticals, biotechnology and healthcare sectors in India by Ernst & Young International. Status of the merger and acquisition activity in the generics industry; Factors that drive changes in the distribution structure of the pharmaceutical sector, including the implementation of value-added tax; Emergence of India as a popular healthcare destination.


Related Articles

  • Report Says Europe Recovering Nicely From Post-Genome Bust…. Moran, Nuala // BioWorld International;4/18/2007, Vol. 12 Issue 16, p4 

    The article focuses on the annual biotech survey by Ernst and Young that revealed 32 initial public offerings and high premiums paid in mergers and acquisitions in the biotechnology sector in Europe. Comments from William Powlett Smith of Ernst and Young are included. It shows that market...

  • Sweeping Changes Ahead for Biotech, Says Ernst & Young.  // BioPharm International;Jul2008, Vol. 21 Issue 7, p12 

    The article focuses on some findings highlighted in "Beyond Borders: Global Biotechnology Report 2008," Ernst & Young's annual report on the trends forming the biotechnology industry. According to the report, 2007 is a very solid year on the financing front for the global biotechnology industry....

  • Despite Challenges, Biotech Staying Positive, Says Ernst & Young. Haniff, Haydia // BioPharm International;Jun2010, Vol. 23 Issue 6, p13 

    The article announces the release of the annual report on the state of the biotechnological industry by Ernst and Young in the U.S.

  • EY: Substantial increase in Hungary M&A in 2013.  // Hungary A.M.;3/28/2014, p1 

    The article discusses the information provided by professional services firm Ernst & Young Global Ltd. on its mergers and acquisitions for Central and Souteastern Europe (CSE) and the number of merger-and-acquisition deals that were made public in 2013.

  • Global consumer M&A activity soars but the UK lags behind.  // Grocer;12/6/2014, Vol. 237 Issue 8184, p9 

    The article discusses a report from research firm EY which shows an increase in global consumer merger and acquisition activity in the third quarter of 2014, but deal values in Great Britain are down by 40 percent.

  • THOSE WACKY SALES TAXES.  // CA Magazine;Apr2004, Vol. 137 Issue 3, p13 

    Presents a list of top 10 Craziest Sales Tax Laws as prepared by Ernst & Young's commodity tax group.

  • More Megadeals Loom In the Drug Industry.  // Mergers & Acquisitions: The Dealermaker's Journal;Apr2000, Vol. 35 Issue 4, p10 

    Reports trends in consolidations between biotechnology companies and pharmaceutical industries in the United States. Deal between American Home Products (AHP) and Pfizer industries; List of other possible partners of AHP; Status of the Glaxo-SmithKline combination; Benefits of the...

  • Attribution of costs. Buckett, Alan; Elliott, Graham // Accountancy;Apr96, Vol. 117 Issue 1232, p92 

    Reports that the British Court of Appeal has found in favor of UBAF in its argument that it should be able to recover value added tax in full on costs associated with acquiring companies that were to make fully taxable supplies. Court of Appeal's challenging of the Customs and Excise...

  • A Learning Moment. BORCHMANN, PHIL // Gulfshore Business;Oct2011, Vol. 16 Issue 10, p8 

    An introduction is presented in which the editor discusses various reports within the issue on topics including company acquisition and prices of goods and services.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics